(Q45110557)

English

A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group

scientific article published in February 1998

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

randomized experiment

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

mixed hyperlipidemia

1 reference

based on heuristic

inferred from title

author name string

McKenney JM

1

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

McCormick LS

2

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Weiss S

3

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Koren M

4

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Kafonek S

5

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Black DM

6

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

language of work or name

0 references

publication date

1 February 1998

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

American Journal of Medicine

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

104

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

137-143

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

randomized experiment

0 references

Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

The triglyceride issue: a view from Framingham

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Nicotinic acid for the treatment of hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Fulminant hepatic failure after ingestion of sustained-release nicotinic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

The role of plasma lipids as predictors of risk for coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

On the rise in low density and high density lipoproteins in response to the treatment of hypertriglyceridaemia in type IV and type V hyperlipoproteinaemias

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Normalisation of the composition of very low density lipoprotein in hypertriglyceridemia by nicotinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

Plasma triglyceride and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900311-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0002-9343(97)00311-2

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45110557&oldid=2066239663"